← Back to patent-cliff list
TT-01488
Tier C — Watch / tradeTT-01488
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BTK
Indications (approved)：Mantle cell lymphoma, B淋巴细胞白血病, B-cell lymphoma
Regional status
US
No progress
2022-06-01
EU
-
China
Phase II
2026-09-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TT-01488?
Approved indications include: Mantle cell lymphoma, B淋巴细胞白血病, B-cell lymphoma.
When does the TT-01488 patent expire?
No public expiry year is available for TT-01488 yet; this page updates once verified.
How do I get a quote for TT-01488 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28